ATE444292T1 - Pyrazolderivate als faktor-xa-inhibitoren - Google Patents

Pyrazolderivate als faktor-xa-inhibitoren

Info

Publication number
ATE444292T1
ATE444292T1 AT03767776T AT03767776T ATE444292T1 AT E444292 T1 ATE444292 T1 AT E444292T1 AT 03767776 T AT03767776 T AT 03767776T AT 03767776 T AT03767776 T AT 03767776T AT E444292 T1 ATE444292 T1 AT E444292T1
Authority
AT
Austria
Prior art keywords
inhibitors
factor
pyrazole derivatives
pyrazole
derivatives
Prior art date
Application number
AT03767776T
Other languages
English (en)
Inventor
Marc Nazar
Volkmar Wehner
David Will
Hans Matter
Original Assignee
Sanofi Aventis Deutschland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP02028915A external-priority patent/EP1433788A1/de
Priority claimed from EP03011308A external-priority patent/EP1479678A1/de
Application filed by Sanofi Aventis Deutschland filed Critical Sanofi Aventis Deutschland
Application granted granted Critical
Publication of ATE444292T1 publication Critical patent/ATE444292T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Surgery (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT03767776T 2002-12-23 2003-12-10 Pyrazolderivate als faktor-xa-inhibitoren ATE444292T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP02028915A EP1433788A1 (de) 2002-12-23 2002-12-23 Pyrazol-Derivate als Faktor Xa Inhibitoren
EP03011308A EP1479678A1 (de) 2003-05-19 2003-05-19 Pyrazolderivate als Faktor-Xa-Inhibitoren
PCT/EP2003/013979 WO2004056815A1 (en) 2002-12-23 2003-12-10 PYRAZOLE-DERIVATIVES AS FACTOR Xa INHIBITORS

Publications (1)

Publication Number Publication Date
ATE444292T1 true ATE444292T1 (de) 2009-10-15

Family

ID=32683809

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03767776T ATE444292T1 (de) 2002-12-23 2003-12-10 Pyrazolderivate als faktor-xa-inhibitoren

Country Status (13)

Country Link
EP (1) EP1581523B1 (de)
JP (1) JP4585448B2 (de)
AR (1) AR042648A1 (de)
AT (1) ATE444292T1 (de)
AU (1) AU2003292218A1 (de)
BR (1) BR0317659A (de)
CA (1) CA2511321A1 (de)
DE (1) DE60329529D1 (de)
IL (1) IL169323A0 (de)
MX (1) MXPA05006200A (de)
PE (1) PE20040925A1 (de)
TW (1) TW200505914A (de)
WO (1) WO2004056815A1 (de)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI372050B (en) 2003-07-03 2012-09-11 Astex Therapeutics Ltd (morpholin-4-ylmethyl-1h-benzimidazol-2-yl)-1h-pyrazoles
ITMI20041032A1 (it) 2004-05-24 2004-08-24 Neuroscienze S C A R L Compositi farmaceutici
DE102004047255A1 (de) * 2004-09-29 2006-04-13 Merck Patent Gmbh Prolinderivate
US7381732B2 (en) 2004-10-26 2008-06-03 Bristol-Myers Squibb Company Pyrazolobenzamides and derivatives as factor Xa inhibitors
JP4912314B2 (ja) 2004-10-26 2012-04-11 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 因子Ｘａ化合物
WO2006050034A1 (en) * 2004-10-29 2006-05-11 Schering Corporation Substituted 5-carboxyamide pyrazoles and [1,2,4]triazoles as antiviral agents
KR101334511B1 (ko) 2004-12-30 2013-11-29 아스텍스 테라퓨틱스 리미티드 Ｃｄｋ, ｇｓｋ 및 오로라 키나아제의 활성을 조절하는피라졸 화합물
EP1724269A1 (de) * 2005-05-20 2006-11-22 Sanofi-Aventis Deutschland GmbH Heteroarylcarbonsäure-sulfamoylalkylamidderivate als Faktor Xa-Inhibitoren
WO2007002563A1 (en) * 2005-06-27 2007-01-04 Exelixis, Inc. Imidazole based lxr modulators
WO2007077435A1 (en) 2005-12-30 2007-07-12 Astex Therapeutics Limited Pharmaceutical compounds
EP2049119A2 (de) 2006-06-29 2009-04-22 Astex Therapeutics Limited Pharmazeutische kombinationen von 1-cyclopropyl-3-[3-(5-morphoolin-4-ylmethyl-1h-benzoimidazol-2-yl)-1h-1-pyrazol-4-yl]-harnstoff
JP5560202B2 (ja) * 2007-12-26 2014-07-23 サノフイ Ｐ２ｙ１２拮抗薬としてのピラゾール−カルボキサミド誘導体
JP5504171B2 (ja) * 2007-12-26 2014-05-28 サノフイ Ｐ２ｙ１２アンタゴニストとしてのヘテロサイクリックピラゾール−カルボキサミド
WO2009123316A1 (ja) 2008-04-04 2009-10-08 武田薬品工業株式会社 複素環誘導体及びその用途
JP5658138B2 (ja) * 2008-04-23 2015-01-21 ライジェル ファーマシューティカルズ， インコーポレイテッド 代謝障害の処置のためのカルボキサミド化合物
TWI532725B (zh) 2010-01-26 2016-05-11 賽諾菲阿凡提斯公司 經氧取代之３－雜芳醯基胺基－丙酸衍生物及其作為藥物之用途
JP6155187B2 (ja) 2010-03-30 2017-06-28 ヴァーセオン コーポレイション トロンビンの阻害剤としての多置換芳香族化合物
AR085013A1 (es) 2011-01-26 2013-08-07 Sanofi Aventis Derivados de acido 3-heteroaroilamino-propionico sustituidos y su uso como sustancias farmaceuticas
TWI523844B (zh) 2011-01-26 2016-03-01 賽諾菲公司 經胺基取代之３－雜芳醯基胺基－丙酸衍生物及其作為藥物之用途
KR20140049020A (ko) 2011-07-26 2014-04-24 사노피 치환된 ３-（티아졸-４-카보닐）- 또는 ３-（티아졸-２-카보닐）아미노프로피온산 유도체 및 이의 약제로서의 용도
ES2560381T3 (es) 2011-07-26 2016-02-18 Sanofi Derivados de ácido 3-heteroaroilamino-propiónico y su uso como productos farmacéuticos
US20130123276A1 (en) 2011-11-14 2013-05-16 Sven Ruf Use of telaprevir and related compounds in atherosclerosis, heart failure, renal diseases, liver diseases or inflammatory diseases
US20130123325A1 (en) 2011-11-14 2013-05-16 Sven Ruf Use of boceprevir and related compounds in atherosclerosis, heart failure, renal diseases, liver diseases or inflammatory diseases
WO2014145986A1 (en) 2013-03-15 2014-09-18 Verseon, Inc. Multisubstituted aromatic compounds as serine protease inhibitors
ES2791749T3 (es) 2013-03-15 2020-11-05 Verseon Corp Halogenopirazoles como inhibidores de la trombina
EP2978754B1 (de) 2013-03-28 2017-05-10 Sanofi Biaryl-propionsäure-derivate und ihre verwendung als arzneimittel
TW201522318A (zh) 2013-03-28 2015-06-16 Sanofi Sa 聯芳基丙酸及其作為醫藥品之用途
EP3184095A1 (de) 2013-05-23 2017-06-28 IP Gesellschaft für Management mbH Verabreichungseinheiten die ein polymorph 1 von 2-(2-methylamino-pyrimidin-4-yl]-1h-indole-5-carboxylic acid [(s)-1-carbamoyl-2-(phenyl-pyrimidin-2-yl-amino)-ethyl]-amide beinhalten
KR20170048410A (ko) 2014-09-17 2017-05-08 베르선 코포레이션 세린 프로테아제 저해제로서의 피라졸릴-치환된 피리돈 화합물
AU2016224974B2 (en) 2015-02-27 2019-09-26 Verseon Corporation Substituted pyrazole compounds as serine protease inhibitors
WO2016202756A1 (en) 2015-06-18 2016-12-22 Bayer Pharma Aktiengesellschaft Substituted 2-(1h-pyrazol-1-yl)-1h-benzimidazole compounds
JOP20190192A1 (ar) * 2017-03-01 2019-08-08 Glaxosmithkline Ip No 2 Ltd مشتقات بيرازول بوصفها مثبطات برومودومين

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6020357A (en) * 1996-12-23 2000-02-01 Dupont Pharmaceuticals Company Nitrogen containing heteroaromatics as factor Xa inhibitors
US5998424A (en) * 1997-06-19 1999-12-07 Dupont Pharmaceuticals Company Inhibitors of factor Xa with a neutral P1 specificity group
US6339099B1 (en) * 1997-06-20 2002-01-15 Dupont Pharmaceuticals Company Guanidine mimics as factor Xa inhibitors
US6268363B1 (en) * 1997-11-28 2001-07-31 Lg Chemical Ltd. Imidazole derivatives having an inhibitory activity for farnesyl transferase and process for preparation thereof
CA2314401A1 (en) * 1997-12-22 1999-07-01 Du Pont Pharmaceuticals Company Nitrogen containing heteroaromatics with ortho-substituted p1's as factor xa inhibitors
CN100340559C (zh) * 1998-12-23 2007-10-03 布里斯托尔-迈尔斯斯奎布药品公司 作为凝血因子xa抑制剂的含氮杂双环
EP1196412B1 (de) * 1999-07-16 2004-06-09 Bristol-Myers Squibb Pharma Company Stickstoff enthaltende heterobicyclen als factor xa inhibitoren
US6632815B2 (en) * 1999-09-17 2003-10-14 Millennium Pharmaceuticals, Inc. Inhibitors of factor Xa
JP2003509412A (ja) * 1999-09-17 2003-03-11 シーオーアール セラピューティクス インコーポレイテッド Ｘａ因子阻害剤
EP1226123A1 (de) * 1999-11-03 2002-07-31 Du Pont Pharmaceuticals Company Cyanao-derivate als faktor xa hemmer
WO2002000647A1 (en) * 2000-06-23 2002-01-03 Bristol-Myers Squibb Pharma Company Heteroaryl-phenyl substituted factor xa inhibitors
AU2001273040A1 (en) * 2000-06-27 2002-01-08 Du Pont Pharmaceuticals Company Factor xa inhibitors
US6750225B2 (en) * 2001-04-18 2004-06-15 Bristol-Myers Squibb Pharms Company 1,4,5,6-tetrahydropyrazolo-[3,4,-c]-pyridin-7-ones useful as factor Xa inhibitors

Also Published As

Publication number Publication date
IL169323A0 (en) 2007-07-04
AU2003292218A1 (en) 2004-07-14
EP1581523A1 (de) 2005-10-05
PE20040925A1 (es) 2004-12-24
CA2511321A1 (en) 2004-07-08
AR042648A1 (es) 2005-06-29
JP4585448B2 (ja) 2010-11-24
MXPA05006200A (es) 2005-08-19
WO2004056815A1 (en) 2004-07-08
BR0317659A (pt) 2005-12-06
EP1581523B1 (de) 2009-09-30
JP2006511608A (ja) 2006-04-06
DE60329529D1 (de) 2009-11-12
TW200505914A (en) 2005-02-16

Similar Documents

Publication Publication Date Title
DE60329529D1 (de) Pyrazolderivate als faktor-xa-inhibitoren
DE60315862D1 (de) Dihydropyridinonderivate als hne-inhibitoren
ATE452891T1 (de) Pyrimidopyrimidone als kinaseinhibitoren
ATE404564T1 (de) Diazepinoindolderivate als kinaseinhibitoren
ATE443054T1 (de) Cyano-pyrrolidine als dpp-iv inhibitoren
ATE489387T1 (de) Pyridoä2,1-aü-isochinolinderivate als dpp-iv inhibitoren
ATE369356T1 (de) Pyridazinon-derivate als cdk2-hemmer
ATE437876T1 (de) Hexahydropyridoisochinoline als dpp-iv- inhibitoren
DK1490355T3 (da) Indolylmaleimidderivater
DE602004008303D1 (de) Triazolopyrimidinderivate als inhibitoren von glycogensynthasekinase-3
ATE538097T1 (de) Als cox-i-inhibitoren geeignete pyrazolderivate
IS7667A (is) Nýjar bensimídazólafleiður
IS7625A (is) Nýjar samrunnar imídazól afleiður
ATE426599T1 (de) Thiazolylpiperidin derivate als mtp inhibitoren
DE602004024420D1 (de) Chinazolinderivate als antitumormittel
ATE400271T1 (de) Aryl-pyridinderivate als 11-beta-hsd1-hemmer
ATE393159T1 (de) Heterobicyclische pyrazolderivate als kinaseinhibitoren
ATE529428T1 (de) Thioxanthinderivate als myeloperoxidaseinhibitoren
ATE420076T1 (de) Indozolonderivate als 11b-hsd1-inhibitoren
ATE538787T1 (de) Benzimidazol-derivative als raf-kinase-hemmer
DE60328978D1 (de) Isochinolinderivate als mao-b inhibitoren
ATE289294T1 (de) Pyrrolidin-derivate als faktor xa inhibitoren
ATE394372T1 (de) G-lactamderivate als prostaglandinagonisten
ATE389658T1 (de) Heterocyclische kondensierte pyrazolderivate als kinaseinhibitoren
NO20014234D0 (no) Pyrazol-3-on-derivater som faktor-Xa-inhibitorer

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties